US Patent
US9107921 — Oral dosage forms for oxygen containing active agents and oxyl-containing polymers
Formulation · Assigned to Spriaso LLC · Expires 2032-01-03 · 6y remaining
Vulnerability score
48/100
Strong — defensible against typical IPR challenges
What this patent protects
This patent protects a pharmaceutical tablet for oral administration that includes a tri-oxy active agent and a release rate controlling non-ionic oxyl-containing hydrophilic polymer.
USPTO Abstract
A pharmaceutical tablet for oral administration once every 12 hours is provided. The tablet includes a first active agent that is a tri-oxy active agent, a second active agent, and a release rate controlling non-ionic oxyl-containing hydrophilic polymer. The tablet is a matrix tablet and a single-dose administration of one or more tablets to a subject under fasted conditions provides a mean CmË for each of the first active agent and the second active agent that is 70% to 135% of a respective mean CmË provided by administering an immediate release oral dosage form to a subject under fasted conditions every 4 to 6 hours over a 12 hour time period, wherein cumulative dosage amounts administered over the 12 hour time period of each active agent is equivalent to the respective amount of each active agent in the pharmaceutical tablet.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.